Creative Medical Technology Holdings Inc (CELZ)

[monte379]

This is what the INVESTORS KNOW about CELZ.
Don’t trust me or anyone on the blogs.
Do you own DD......

The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem® has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem® ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures. This will become incredibly important as CELZ moves forward.

CaverStem® has been shown to be effective even in patients who do not respond to PDE5 inhibitors, and, unlike PDE5 inhibitors, CaverStem® and FemCelz® is completely safe.

Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk, Sanderson and Hassid). Currently you can make an appointment any of those locations along with Dr. Antonini in Rome, Italy.

Two shareholders are among the treated patients and can confirm the ease of the treatment for the patient. Testimonials have been published showing patients have been treated. Follow up testimonials will be published when ready.

CELZ will continually add the new physicians to the CaverStem® website as they come aboard. Interest has been growing across the US and Europe.

To speed up new physician training due to the demand, CELZ added additional medical personnel to travel to each physicians office/area to train.

Due to the increased international demand and to compliment the existing relationship with Scott Shea, Thomas Bianchi has joined the company as the international sales representative. DD will tell you that interest in increasing in Europe.

Marketing Director David Brandt has been interviewing patients and is preparing customer testimonial videos. The first ones were posted this week.

CELZ has started treating the first patients with the FemCelz® procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem® affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz® program.

Over 50 domain names have been registered showing that more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.

CELZ has begun a series of mailer and email campaigns introducing the CaverStem® procedure to licensed physicians in the areas of urology, OB/GYN, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CELZ reported good replies from the emails.

CELZ has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting television commercials which will be edited to direct patients to each physician in their area. This will become very important as Google ads has cracked down in stem cell treatment advertisements that are not back by a clinical study. CaverStem® will have their clinical study published very soon and will greatly benefit from this.

U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results, however Government exemptions are required for the ongoing import of the device in Russia. This is a slow and tedious process in getting approval, therefore CELZ progress has been delayed in Russia.

Your DD will show that The current Doctors have been performing the procedure with EXCELLENT results…Up to 90% success rate, even in difficult patients. CELZ has received positive feedback from all treating physicians of a 70% to 90% efficacy in their patients. Obviously results differ depending on the age and health of the patient and cause and severity of their erectile dysfunction.

A one-year trial has concluded and will PROVE the same results. You can watch for results here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14

CELZ submitted their paper for publication. The Principal Investigator is Dr. Jacob Rajfer, MD University of California, Los Angeles... top notch credentials. This is ongoing and in compliance with contractual obligations. Once the paper has been approved by The Journal of Translational Medicine and a publication date advised, shareholders will be updated. Additionally, CELZ has designed an electronic patient registry that is intended to include data from the clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and the second generation, needle only. This was updated in September 2019 expanded to 140 patents and will be published very soon.

Revenue has now started, CELZ is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. Evidence of this are the scores of patients treated in Rome and NM. From these revenue streams, CELZ anticipates reaching financial self-sufficiency by revenues from sales in 2019.

CELZ signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem® and FemCelz® will generate. This has generated many calls to the vetted doctors.

CELZ anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStem® and FemCelz®), incontinence and infertility. This brand will compliment the CaverStem® and FemCelz® brands.

CaverStem® and FemCelz® are just TWO of SEVERAL patents and patents pending held by CMTH. 4 NEW patents were applied for in 2018.

CELZ anticipates commercialization of StemSpine® in late 2019 or early 2020 bringing online a third revenue source.

Management has already successfully commercialized Medistem providing a large return on investment for the shareholders.

CaverStem®, FemCelz®, StemSpine® & AmnioStemTM have all be TRADEMARKED

We KNOW Caverstem® + FemCelz®+ StemSpine®+ AmnioStemTM will = NASDAQ in time.